Abbott’s Exact Sciences-led diagnostics expansion, durable medtech moat, and 16.3x forward P/E create an attractive long-term compounding opportunity despite litigation and leverage risks.
Overview
Abbott Laboratories is a diversified healthcare compounder spanning Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals, with international markets representing approximately 61% of sales and emerging markets 37%. Its portfolio combines recurring consumables, high-switching-cost laboratory systems, trusted consumer brands, and branded generics. The central strategic development is the March 23, 2026, $21 billion Exact Sciences acquisition, which adds leadership in colorectal screening and precision oncology through Cologuard, Oncotype DX, and Oncodetect. **The transaction temporarily dilutes adjusted EPS by approximately $0.20 but raises Abbott’s long-term growth ceiling.** Q2 2026 revenue increased 13.0% reported and 4.8% organically to $12.593 billion, while adjusted EPS of $1.31 exceeded consensus by $0.03 and adjusted gross margin expanded 100 basis points to 58.0%. Management raised 2026 adjusted EPS guidance to $5.45-$5.60 and maintained comparable sales growth guidance of 6.5%-7.5%. At approximately 16.3x forward 2026 adjusted EPS and 3.1x sales, valuation is below historical and large-cap peer averages. The principal catalysts are Exact Sciences integration, international Cologuard Plus adoption, Volt PFA share gains, and progress on Similac litigation.